コンテンツへスキップ
Merck
  • Regulation of valve endothelial cell vasculogenic network architectures with ROCK and Rac inhibitors.

Regulation of valve endothelial cell vasculogenic network architectures with ROCK and Rac inhibitors.

Microvascular research (2015-02-11)
C Alexander Arevalos, Amanda T Walborn, Amanda A Rupert, Jonathan M Berg, Elizabeth L Godfrey, Jacqueline M V Nguyen, K Jane Grande-Allen
要旨

The age- and disease-dependent presence of microvessels within heart valves is an understudied characteristic of these tissues. Neovascularization involves endothelial cell (EC) migration and cytoskeletal reorientation, which are heavily regulated by the Rho family of GTPases. Given that valve ECs demonstrate unique mesenchymal transdifferentiation and cytoskeletal mechanoresponsiveness, compared to vascular ECs, this study quantified the effect of inhibiting two members of the Rho family on vasculogenic network formation by valve ECs. A tubule-like structure vasculogenesis assay (assessing lacunarity, junction density, and vessel density) was performed with porcine aortic valve ECs treated with small molecule inhibitors of Rho-associated serine-threonine protein kinase (ROCK), Y-27632, or the Rac1 inhibitor, NSC-23766. Actin coordination, cell number, and cell migration were assessed through immunocytochemistry, MTT assay, and scratch wound healing assay. ROCK inhibition reduced network lacunarity and interrupted proper cell-cell adhesion and actin coordination. Rac1 inhibition increased lacunarity and delayed actin-mediated network formation. ROCK inhibition alone significantly inhibited migration, whereas both ROCK and Rac1 inhibition significantly reduced cell number over time compared to controls. Compared to a vascular EC line, the valve ECs generated a network with larger total vessel length, but a less smooth appearance. Both ROCK and Rac1 inhibition interfered with key processes in vascular network formation by valve ECs. This is the first report of manipulation of valve EC vasculogenic organization in response to small molecule inhibitors. Further study is warranted to comprehend this facet of valvular cell biology and pathology and how it differs from vascular biology.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
L-アスコルビン酸, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L-アスコルビン酸, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
ストレプトマイシン 硫酸塩, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
L-アスコルビン酸, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
臭化エチジウム 溶液, BioReagent, for molecular biology, 10 mg/mL in H2O
Sigma-Aldrich
L-アスコルビン酸, reagent grade, crystalline
USP
アスコルビン酸, United States Pharmacopeia (USP) Reference Standard
Supelco
L-アスコルビン酸, analytical standard
Sigma-Aldrich
L-アスコルビン酸, reagent grade
Sigma-Aldrich
臭化エチジウム, BioReagent, for molecular biology, powder
Sigma-Aldrich
臭化エチジウム 溶液, BioReagent, for molecular biology, 500 μg/mL in H2O
Sigma-Aldrich
L-アスコルビン酸, 99%
Sigma-Aldrich
L-アスコルビン酸, meets USP testing specifications
Sigma-Aldrich
カルセイン AM, suitable for fluorescence, BioReagent, ≥90% (HPLC)
Supelco
アスコルビン酸, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-アスコルビン酸, FCC, FG
Sigma-Aldrich
L-アスコルビン酸, ACS reagent, ≥99%
Sigma-Aldrich
4-ビニル-1,3-ジオキソラン-2-オン, 99%
Sigma-Aldrich
ストレプトマイシン 硫酸塩, powder, BioXtra, suitable for mouse embryo cell culture
Sigma-Aldrich
ストレプトマイシン 硫酸塩, powder
Sigma-Aldrich
L-アスコルビン酸, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
カルセイン AM, Small Package (20 X 50 μg ), ≥95.0% (HPLC)
Sigma-Aldrich
臭化エチジウム 溶液, for fluorescence, ~1% in H2O
Sigma-Aldrich
フェノールレッド, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
フェノールレッド, ACS reagent
Sigma-Aldrich
臭化エチジウム, ~95% (HPLC)
Sigma-Aldrich
L-アスコルビン酸, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Sigma-Aldrich
Streptomycin Ready Made Solution, 100 mg/mL in water
Sigma-Aldrich
臭化エチジウム 溶液, 10 mg/mL
アスコルビン酸, European Pharmacopoeia (EP) Reference Standard